1
Clinical Trials associated with Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T Cells(First Affiliated Hospital of Zhejiang University)A Single-arm, Open-label, Dose Escalation Study to Explore Safety, Efficacy and Pharmacokinetics of Autologous Humanized Anti-CD19 and Anti-CD20 Dual Specific CAR-T Cells in Adult Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
This is a single-arm, open-label, dose escalation, phase I study, aiming to evaluate the safety and efficacy of Autologous Humanized Anti-CD19 and Anti-CD20 Dual Specific Chimeric Antigen Receptor (CAR) T-cells in patient with relapsed or refractory diffuse B cell lymphoma.
100 Clinical Results associated with Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T Cells(First Affiliated Hospital of Zhejiang University)
100 Translational Medicine associated with Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T Cells(First Affiliated Hospital of Zhejiang University)
100 Patents (Medical) associated with Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T Cells(First Affiliated Hospital of Zhejiang University)
100 Deals associated with Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T Cells(First Affiliated Hospital of Zhejiang University)